lumateperone, schizophrenia, depression conference Thanks, Juan. candidate associated thank an and treatment our of with stage dementia, for update for Good on everyone, disease. for Today bipolar including lead today's you drug is clinical and development which in the Alzheimer's will us we call. provide late joining morning, agitation
our discuss inhibitor, recently Parkinson’s then target will detail PDEX with time entered program in patient in population. has disease We clinical development this ITI-XXX, for our the first which
Lastly, program pain. our for will for to advancement three including preclinical recently use developed opioid triple with Larry including being substance us programs. we and which the resources financial offering, disorder the then substantial our will ITI-XXX addiction completed results, discuss novel or of our continue provides review public
will We the for then open line Q&A.
the program controlled controlled efficacy schizophrenia lumateperone includes placebo supportive double-blind a and data trial Our conducted randomized United trials in from double-blind positive States. placebo third large two
as the and two Importantly with control frequently statistically weight risperidone superior tolerability schizophrenia. in In profile and demonstrated and the differentiated gain. most such versus included safety several on tolerability risperidone to studies lumateperone key lumateperone the for triglycerides, risperidone, parameters treatment significantly of anti-psychotic an prolactin a these as studies, prescribed glucose, act was of safety cholesterol,
to one In in addition, long-term ongoing. to we part lumateperone a exposed patients similar placebo. with to-date for been study stable X,XXX lumateperone year a second open tolerated over the our profile is switching schizophrenia treated and up study week study, this label completed the safety safety recently well of safety with study, With has six
lumateperone new lumateperone for earlier this schizophrenia We drug received regarding in encouraged favorable submit efficacy NDA by the guidance for previously FDA planned of treatment by the mid-XXXX. to generated and announced intend the application, are data And we safety our following studies. year schizophrenia as our
total need with tolerated switched parameters safety symptoms this well and significant our details. Negative data safety the of in schizophrenia study titration this study six population. previous subgroups lumateperone treatment schizophrenia We of our this without stable in study, patients placebo the the you elevated patients safety switch schizophrenia weight, did stable press from in It antipsychotics provide of most not for worsen and study symptoms standard-of-care world about schizophrenia open-label a those that standard-of-care study mean comorbid were from are body of for in conducted stable that with with were which statistically acutely with upon results, is improvement this for the to to was safety outpatient depression lumateperone six-week weeks and was symptoms. back patients switched from switching with switched in patients where baseline to reflected again real dose profile schizophrenia, greater profile results also their In excited consistent we was exacerbated cardiometabolic These improvements in to prominent with with to recent Syndrome PANSS an as significant the standard-of-care. Notably, refer symptomatology patient are improvements from with patients I medication. to further Scale when favorable endocrine with Positive extends score. observed negative those Statistically observed favorable. release X, September lumateperone in worsened Lumateperone and profile when of notable similar stable standard-of-care were generally observed and in from lumateperone. to setting. Rather, such symptoms
ACNP We meeting. this of American analysis will College the provide at further later year Neuropsychopharmacology
medical NMDA development scientific In presented update in forward. continue you our is formulation lumateperone ITI-XXX programs we safety lumateperone receptor channels International made disorders At meeting with long-acting standalone important and antidepressant oral in and patients. an of via advance at range and DX our these conferences. AMPA Society data injectable agent, data regarding the program. as in some itself This demonstrating that rapid we indirectly as a prefrontal lend a potential the through numerous resistant to program differentiated the that the of move we supporting continue and tolerability will shared The We at to and suggest data neurotransmission may injectable months, option We being to Bipolar cortex we’ve glutamatergic to-date College activation. for presentations long-acting development a Neuropsychopharmacology lumateperone's lumateperone, mood lumateperone recent treatment International of at and both and pre-clinical other as Conference thematic depression. Annual on the enhances meetings, of a dopamine Disorders potent for
for to comorbid disorder depression. rapid major transporter in and described disorders presented activate lumateperone inhibition safety potent demonstrating the depressive rapid which depression has the and effects, lumateperone These effects that findings, pathway ketamine, bipolar with key addition suffering concerns. associated we a the suggest to shown in patients has proteins antidepressant data ketamine-like range yet mTOR lumateperone, depression, from of similar to Additionally, been with in potential including treatment-resistant lumateperone potent mood schizophrenia, previously antidepressant and exhibit serotonin not
X.X living million relevant the in or United bipolar consists people Our study. to study in States X.X% XXXX. of of adults in Bipolar safety monotherapy safety are depression the and tolerability. few terms X lumateperone for Phase favorably approximately studies a anticipate global monotherapy lumateperone adjunctive the bipolar patient States, of and they the believe conducted there the have We in depression approved affects will in United an program clinically completing enrollment these disorder three to-date a therapies with clinical bipolar limitation States, depression. We translate treatment and study of conducted in United trials: seen profile
disorder from our program depressive to and we depression. of are treatment lumateperone to major planning treatment-resistant disorders evaluate Additionally, broaden depressive the including
of for enter as will lumateperone program We updates, this clinic year. the as indications next in expansion progresses exciting further and we those provide the
and this behavioral treatment and aggressive no fractures of and are effects and array our provide to and to These with and in provides is is of are is agitation necessary represents disease institutionalization. to increased frequently over agitation our need Moving symptoms Phase also these aggression blockade with patients behavioral low We certain those including treatments broad provides the DX relief that receptor which ineffective disease uniquely control believe a the and prescribed Alzheimer’s dose ongoing; deleterious X a program, a behaviors with to observed cause program the development for medications of but dementia associated dementia, lumateperone, prevalent safety dementia. There highly positioned off-label this saturation and lumateperone profile population. with mortality. for of agitation and and approved medications complete leading receptor manage modest associated of with tolerability half patient side patients favorable for in X-HTXA including leading are Currently, falls symptoms. address for Alzheimer’s of unmet
turn is to ITI-XXX PDE reduce demonstrated recently PDEX nursing our the goal selective Our costly CNS of to in CNS. reducing platform, givers on on I’d of or phosphodiesterase delaying therapeutic program. lead clinical patients, the care across to diseases. the or burden and of by PDEX in significant In potent function, ITI-XXX and and preclinical like X now of inhibitors of inhibitor primary our our and variety home The the we and a mechanism is placements. PDEX and preventing suggests regulating study, cells have immune potential action and non-CNS microglia importance in neuroinflammation inhibition PDEX a families
these at while in doses diseases will replacement that inhibitors modifying at PDEX in data disease Neuroscience including progression treatments. meeting of symptom Parkinson’s suggest dyskinesia in disease, of strong utility neurodegenerative inhibiting symptoms ITI-XXX components. Society this We the treating allow neuroinflammation These suggest of PDEX induced inhibition the additional Alzheimer’s motor mechanism week. ITI-XXX neuroinflammatory other Parkinson’s for be that and data lower a disease the diseases for by our having models presenting may adverse next dopamine on and and disease Preclinical therapy control of have
PDEX symptoms improvement clinical as evaluate results, X/X tolerability Parkinson’s on stable the patients Parkinson’s have ITI-XXX. to demonstrating study recently sleepiness, as trial, days. over other of potential in non-motor shown Based this trial preclinical have schizophrenia, models for symptoms. of this of Additional Phase these double-blind, for such patients mild-to-moderate primary in oral our dose cognitive seven normal once-daily patients with non-motor multiple volunteers function X safety disease XXX who and with safety objective is address prevalent Phase are and we excessive Parkinson’s Parkinson’s to as in reduction initiated ITI-XXX on well In disease daytime The healthy data maintained in the doses evaluate a XXX attenuation disease. in clinical inhibitors disease randomized, rising receive to placebo-controlled, therapy with and our
Parkinson’s mediators to disease. ITI-XXX with symptoms Secondary biomarkers potential explore of symptoms potential as profile pharmacokinetic of associated non-motor evaluate assessed the of to utility neuroinflammation. control to will Plasma objectives motor inflammatory its be levels and and are
impairing million primarily therapies replacement in focused people neurons brain largely psychosis, progressive neurodegenerative by Future non-motor efficacy expect million this depression, people complete U.S. affects and symptoms including examine X in studies dopamine cognition. and and disorder addressing motor Current to in and on the may in X.X We symptoms. mid-XXXX. dopamine function. a It nearly enrollment affecting sleep disease disturbances, Europe. dysautonomia trial is non-motor Parkinson’s motor
time over doses and motor commonly However, need control to maintain be therapies following these increased the dyskinesia. treatment of long-term patients to develop
non-motor prevalent are symptoms in highly disease. Parkinson’s Additionally,
dysautonomia XX% under For treated example, excessive and often and XX% affect non-motor limited and These daytime an under important symptoms to due the patients. of sleepiness disability options cause to available. These of patient recognized therapeutic affects up symptoms to of distress. up partially are represent caregiver patients
We and are both non-motor ITI-XXX this symptoms of the motor address about encouraged possibility of to disease.
ITI-XXX of not with Parkinson’s of Parkinson’s is and as disease for potential through do comorbidities, our development other neuroprotective reduction potential associated psychiatric disorders, triple valuating valuating benefits to It treatment is clinical with therapeutic neuroinflammation. Together on the to threat. Importantly, or programs, Shifting substance Triple clinical interventions. anxiety. disease, candidate three pain symptoms disease on and designed currently preclinical continue we the novel a depression use of available development modifying effects develop treatments disease including the therefore PDEX critical inhibition are approaches for focused progression. we modify
also with a to challenges. deaths which XX,XXX functions of effects As while for treatments ITI-XXX unique and preclinical substance these States new drugs In deaths is receptors. behavioral reversible and U.S. is pressing in opioid a in ITI-XXX with we’re crisis a humans. by resulted effective receptors, with XXXX the is exists address and There ITI-XXX are to to treatment believe now studies, addiction translated the at in successfully yield This need aware to very all displaying acts the non-addictive agonist that interaction United XXXX abuse new attenuating and Naloxone. potential develop utility may as studies manage X-HTXA safe, treat partial antagonist use as new U.S. opiate the We than XXXX more at opiate disorder profile between faced pain. analgesic morphine substance and XXX,XXX DX to of an efficacy safety It’s in unparalleled ongoing. clinical over currently pain. pharmacologic Preclinical antagonist
position recent the we who advance in with financial proceeds investments for our and $XXX.X I review million very third strong our financing, Finally, ended the to in quarter net million over a quarter. places activity. call from us in coupled with will results turn cash the $XXX corporate which now will the Larry, to
